Duminuco Andrea, Maugeri Cinzia, Parisi Marina, Mauro Elisa, Fiumara Paolo Fabio, Randazzo Valentina, Salemi Domenico, Agueli Cecilia, Palumbo Giuseppe Alberto, Santoro Alessandra, Di Raimondo Francesco, Vetro Calogero
Postgraduate School of Hematology, University of Catania, 95123 Catania, Italy.
Division of Hematology, A.O.U. "Policlinico G.Rodolico-S.Marco", 95123 Catania, Italy.
Cancers (Basel). 2022 Apr 27;14(9):2186. doi: 10.3390/cancers14092186.
FMS-like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase family member. Mutations in , as well known, represent the most common genomic alteration in acute myeloid leukemia (AML), identified in approximately one-third of newly diagnosed adult patients. In recent years, this has represented an important therapeutic target. Drugs such as midostaurin, gilteritinib, and sorafenib, either alone in association with conventional chemotherapy, play a pivotal role in AML therapy with the mutated gene. A current challenge lies in treating forms of AML with extramedullary localization. Here, we describe the general features of myeloid sarcoma and the ability of a targeted drug, i.e., gilteritinib, approved for relapsed or refractory disease, to induce remission of these extramedullary leukemic localizations in AML patients with mutation, analyzing how in the literature, there is an important development of cases describing this promising potential for care.
FMS样酪氨酸激酶3（FLT3）是受体酪氨酸激酶家族成员。众所周知，[FLT3]突变是急性髓系白血病（AML）中最常见的基因组改变，在大约三分之一新诊断的成年患者中被发现。近年来，这已成为一个重要的治疗靶点。诸如米哚妥林、吉列替尼和索拉非尼等药物，单独使用或与传统化疗联合使用，在伴有[FLT3]基因突变的AML治疗中发挥着关键作用。目前的一个挑战在于治疗具有髓外定位的AML形式。在此，我们描述了髓系肉瘤的一般特征，以及一种被批准用于复发或难治性疾病的靶向药物吉列替尼，诱导具有[FLT3]突变的AML患者这些髓外白血病定位缓解的能力，并分析在文献中，描述这种有前景的治疗潜力的病例是如何有重要进展的。
